We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03853616
Recruitment Status : Recruiting
First Posted : February 25, 2019
Last Update Posted : December 1, 2021
Sponsor:
Information provided by (Responsible Party):
Miltenyi Biomedicine GmbH

Brief Summary:
This is a phase l/ll multi-centric, single arm, prospective open, dose-escalation study in patients with relapsed or refractory CD19-positive B cell malignancies (ALL, NHL, CLL). The trial will include adult and pediatric patients. The trial consists of 2 parts: Part I and Part II. In total approximately 48 patients will be included in Part I of the trial. There will be three individual cohorts, defined by disease biology: pediatric ALL and aggressive pediatric NHL (Cohort 1), adult ALL (Cohort 2) and adult NHL/CLL (Cohort 3).

Condition or disease Intervention/treatment Phase
Acute Lymphoblastic Leukemia Recurrent B-cell Lymphoma Recurrent B-cell Lymphoma Refractory Chronic Lymphocytic Leukemia Recurrent Chronic Lymphocytic Leukemia Refractory Biological: MB-CART19.1 Phase 1 Phase 2

Detailed Description:

The Part I (Phase I) will evaluate the safety of the MB-CART19.1 and determine the recommended dose levels for the Part II (Phase II) efficacy evaluation in each of the three disease cohorts.

Dose evaluation will start in Cohorts 1 and 2 with Dose Level 1 and in Cohort 3 with Dose Level 2, sparing Dose Level 1 (see figure 1). Each of the cohorts will evaluate the safety of MB-CART19.1.

In each dose level of each of the three cohorts three 3 + 3 patients will be treated. A particular dose level will be expanded to 6 patients if one patient out of 3 patients treated at that particular dose level develops DLT. Once this occurs, further dose-escalations are halted until the dose has proven to be safe in the expanded cohort. If 2 or more in a cohort of 6 patients develop DLT no further dose escalation is allowed, and the next lower dose level will be expanded to 6 patients in total. The highest dose among the dose levels tested at which no more than one out of six patients experiences DLT will be considered the MTD. In Dose Level 3, three additional patients will be treated, if no DLT occurred. Dose Level 0 will be tested only if Dose Level 1 is not tolerable.

Cohort 3 will Start with Dose Level 2. If Dose Level 2 is not tolerated, Dose Level 1 will be tested. DLT will be evaluated within 4 weeks after the infusion of MB-CART19.1. An interval of at least 28 days between the treatment of the first and the second patient in each dose level (and in each cohort) is mandatory.

Part II (Phase II) will evaluate the efficacy and safety in patients treated with the recommended dose in Cohorts 1 to 3, respectively. After review of completed day 28 safety and efficacy data within Part I (Phase I) by the SMB, the design of Phase II, specifically the number and types of Phase II cohorts and the recommended dose level(s) for Phase II will be determined and thus, the number of patients to be treated will be calculated.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Safety, Dose Finding and Feasibility Trial of MB-CART19.1 in Patients With Relapsed or Refractory CD19 Positive B Cell Malignancies
Actual Study Start Date : November 26, 2018
Estimated Primary Completion Date : August 2022
Estimated Study Completion Date : December 2022


Arm Intervention/treatment
Experimental: Phase I: DL 0: 1x10e5 MB-CART19.1 cells
In each dose level of each of the three cohorts three 3 + 3 patients will be treated. A particular dose level will be expanded to 6 patients if one patient out of 3 patients treated at that particular dose level develops DLT. Once this occurs, further dose-escalations are halted until the dose has proven to be safe in the expanded cohort. If 2 or more in a cohort of 6 patients develop DLT no further dose escalation is allowed, and the next lower dose level will be expanded to 6 patients in total. The highest dose among the dose levels tested at which no more than one out of six patients experiences DLT will be considered the MTD.
Biological: MB-CART19.1
MB-CART19.1 consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD19-positive tumor cells in b cell malignancies
Other Names:
  • CD19-targeting CAR T cells
  • Anti-CD19 CAR T cells

Experimental: Phase I: DL 1: 5x10e5 MB-CART19.1 cells
Dose evaluation will start in Cohorts 1 and 2 with Dose Level 1. In each dose level of each of the three cohorts three 3 + 3 patients will be treated. A particular dose level will be expanded to 6 patients if one patient out of 3 patients treated at that particular dose level develops DLT. Once this occurs, further dose-escalations are halted until the dose has proven to be safe in the expanded cohort. If 2 or more in a cohort of 6 patients develop DLT no further dose escalation is allowed, and the next lower dose level will be expanded to 6 patients in total. The highest dose among the dose levels tested at which no more than one out of six patients experiences DLT will be considered the MTD.
Biological: MB-CART19.1
MB-CART19.1 consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD19-positive tumor cells in b cell malignancies
Other Names:
  • CD19-targeting CAR T cells
  • Anti-CD19 CAR T cells

Experimental: Phase I: DL 2: 1x10e6 MB-CART19.1 cells
Dose evaluation will start in Cohort 3 with Dose Level 2, sparing Dose Level 1. If Dose Level 2 is not tolerated, Dose Level 1 will be tested. In each dose level of each of the three cohorts three 3 + 3 patients will be treated. A particular dose level will be expanded to 6 patients if one patient out of 3 patients treated at that particular dose level develops DLT. Once this occurs, further dose-escalations are halted until the dose has proven to be safe in the expanded cohort. If 2 or more in a cohort of 6 patients develop DLT no further dose escalation is allowed, and the next lower dose level will be expanded to 6 patients in total. The highest dose among the dose levels tested at which no more than one out of six patients experiences DLT will be considered the MTD.
Biological: MB-CART19.1
MB-CART19.1 consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD19-positive tumor cells in b cell malignancies
Other Names:
  • CD19-targeting CAR T cells
  • Anti-CD19 CAR T cells

Experimental: Phase I: DL 3: 3x10e6 MB-CART19.1 cells
In each dose level of each of the three cohorts three 3 + 3 patients will be treated. A particular dose level will be expanded to 6 patients if one patient out of 3 patients treated at that particular dose level develops DLT. Once this occurs, further dose-escalations are halted until the dose has proven to be safe in the expanded cohort. If 2 or more in a cohort of 6 patients develop DLT no further dose escalation is allowed, and the next lower dose level will be expanded to 6 patients in total. The highest dose among the dose levels tested at which no more than one out of six patients experiences DLT will be considered the MTD. In Dose Level 3, three additional patients will be treated, if no DLT occurred. Dose Level 0 will be tested only if Dose Level 1 is not tolerable.
Biological: MB-CART19.1
MB-CART19.1 consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD19-positive tumor cells in b cell malignancies
Other Names:
  • CD19-targeting CAR T cells
  • Anti-CD19 CAR T cells

Experimental: Phase II - Recommended dose MB-CART19.1
Phase II will evaluate the efficacy and safety in patients treated with the recommended dose in Cohorts 1 to 3, respectively.
Biological: MB-CART19.1
MB-CART19.1 consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD19-positive tumor cells in b cell malignancies
Other Names:
  • CD19-targeting CAR T cells
  • Anti-CD19 CAR T cells




Primary Outcome Measures :
  1. Phase I - Determination of the recommended dose of MB-CART19.1 [ Time Frame: until day 28 after infusion of MB-CART19.1 ]
    Determined on the basis of the maximum tolerated dose (MTD); MTD is defined as the highest dose level at which < 33% of patients experience Dose Limiting Toxicity (DLT). Safety and toxicity assessment of MB-CART19.1 per adverse events (AE) reporting classified according to CTCAE version 5.0

  2. Phase II - Determination of the Overall Response Rate (ORR) [ Time Frame: 28 days after infusion of MB-CART19.1 (and at month 3 in NHL patients not in CR on day 28) ]
    ORR in ALL patients is defined as the rate of complete remission (CR, CRh); ORR in NHL patients is defined as the rate of overall response (CR or PR)


Secondary Outcome Measures :
  1. Phase I - Overall incidence and severity of adverse events [ Time Frame: throug study completion, an average of 5 years ]
    per adverse events (AE) reporting classified according to CTCAE version 5.0

  2. Phase I - Response to treatment for each timepoint [ Time Frame: day 28 ]
    ORR in ALL (Rate of CR/CRh)

  3. Phase I - Response to treatment for each timepoint [ Time Frame: day 28, week 12, month 6, 1 year ]
    Rate MRD-negative CR in ALL

  4. Phase I - Response to treatment for each timepoint [ Time Frame: day 28, patients not in CR on day 28: month 3 ]
    ORR in NHL/CLL (Rate of CR/PR)

  5. Phase I - Occurence of B-cell depletion [ Time Frame: through study completion, an average of 5 years ]
    Circulating B cell numbers

  6. Phase I - Phenotype and persistence of MB-CART19.1 [ Time Frame: days 2, 7, 10, 14, 28, weeks 8, 12, months 6, 12, 24, 36, 48, 60 ]
    Blood samples for determination of persistence/phenotyping of infused MB-CART19.1 will be analysed.

  7. Phase II - Overall incidence and severity of adverse events [ Time Frame: through study completion, an average of 5 years ]
    per adverse events (AE) reporting classified according to CTCAE version 5.0

  8. Phase II - Number of patients with successful MB-CART19.1 production [ Time Frame: day 0 ]
    Number of patients meeting the inclusion criteria and none of the exclusion criteria for who an autologous MB-CART19.1 product can be generated

  9. Phase II - Rate of ALL patients achieving MRD negative CR [ Time Frame: day 28, week 12, month 6, 1 year ]
    Rate MRD-negative CR in ALL

  10. Phase II - Duration of response [ Time Frame: through study completion, an average of 5 years ]
    Determination of response rate

  11. Phase II - Disease-free survival [ Time Frame: at 1 year after MB-CART19.1 infusion in patients not receiving alloSCT ]
    Determination of survival and relapse

  12. Phase II - Occurrence of B cell depletion [ Time Frame: days 7, 10, 14, 28, weeks 8, 12, 16, months 6, 8, 10, 12, 24, 36, 48, 60 ]
    Circulating B cell numbers in the peripheral blood will be assessed by Flow cytometry.

  13. Phase II - Phenotype and persistence of MB-CART19.1 [ Time Frame: days 2, 7, 10, 14, 28, weeks 8, 12, months 6, 12, 24, 36, 48, 60 ]
    Blood samples for determination of persistence/phenotyping of infused MB-CART19.1 will be analysed.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Year and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female patients must have r/r CD19-expressing ALL or NHL/CLL
  • CD19 expression must be detected on the malignant cells by flow cytometry (leukemia, malignant effusion in NHL) or immunohistochemistry (NHL);
  • Age ≥ 1 year (if deemed fit by treating investigator);
  • Absolute CD3+ T cell count ≥100/μl;
  • ECOG performance score of 0-2 if >16 years old, or Lansky performance score of >50 if ≤16 years old at screening;
  • No active Hepatitis B, Hepatitis C, HIV1/2;
  • No childbearing potential or negative pregnancy test at screening and before chemotherapy in women with childbearing potential;
  • Signed and dated informed consent/assent by patients
  • and meet the following disease-specific criteria:

ALL:

  • patients with >5% blasts in BM (M2 or M3) after at least one standard chemotherapy and one salvage regimen who are ineligible for allogeneic stem cell transplant (alloSCT) or have refractory disease activity precluding alloSCT at this time, or
  • patients who have relapsed post alloSCT at least 100 days posttransplant, with no evidence of active GVHD, and no longer taking immunosuppressive agents for at least 30 days prior to enrollment.
  • patients with Ph+ ALL if they are intolerant to tyrosine kinase inhibitor (TKI) therapy, or if they have r/r disease after treatment with at least 2 different TKIs.
  • ALL patients with combined bone marrow and CNS and/or testicular relapse are eligible only if the extramedullary disease has been successfully cleared by conventional therapy at the time of inclusion (e.g. intrathecal chemotherapy, orchiectomy).

Pediatric aggressive NHL (1-17 years):

  • patients after at least one salvage chemotherapy as bridge to alloSCT or
  • patients ineligible for alloSCT or
  • patients who have relapsed post alloSCT at least 100 days posttransplant, with not evidence of active GVHD, and no longer taking immunosuppressive agents for at least 30 days prior to enrollment.
  • patients with CNS disease (excluding isolated CNS lymphoma) are eligible only if disease has been successfully cleared by intrathecal chemotherapy at the time of inclusion.

Adult NHL:

  • patients after at least one standard chemotherapy and one salvage regimen as bridge to alloSCT or
  • patients who are ineligible for alloSCT or
  • patients who have relapsed post alloSCT at least 100 days posttransplant, with no evidence of active GVHD, and no longer taking immunosuppressive agents for at least 30 days prior to enrollment.
  • patients with CNS disease (excluding isolated CNS lymphoma) are eligible only if disease has been successfully cleared by intrathecal chemotherapy at the time of inclusion.

CLL:

  • patients with r/r disease after established and approved treatment options have failed.
  • patients not eligible or appropriate for conventional alloSCT.

Exclusion Criteria:

  • Isolated CNS or testicular relapse in ALL;
  • Isolated CNS lymphomas;
  • Active solid brain metastases or history of solid brain metastases
  • Current autoimmune disease, or history of autoimmune disease with potential CNS involvement;
  • Active clinically significant CNS dysfunction (including but not limited to uncontrolled seizure disorders, cerebrovascular ischemia or hemorrhage, dementia, paralysis);
  • History of an additional malignancy other than non-melanoma skin cancer or carcinoma in situ unless disease free for ≥3 years;
  • Pulmonary function: Patients with pre-existing severe lung disease or an oxygen requirement of >28% O2 supplementation or active pulmonary infiltrates on chest X-ray;
  • Cardiac function: Fractional shortening <28% or left ventricular ejection fraction <50% by echocardiography;
  • Renal function: GFR ≤29 mL/min/1.73 m2 by CKD-EPI for patients 18 yrs (Levey et al. 2009) or creatinine clearance ≤29 mL/min/1.73 m2 by Schwartz formula (Schwartz et al. 1976) for patients <18 yrs of age;
  • Liver function: Patients with a serum bilirubin >3 times upper limit of normal or an AST or ALT > 5 times upper limit of normal, unless due to leukemic liver infiltration in the estimation of the investigator;
  • Rapidly progressive disease that in the estimation of the investigator would compromise ability to complete study therapy;
  • Pregnant or breast-feeding females;
  • Medications:

    • Systemic chemotherapies, corticosteroids with the exception of physiologic replacement dosing, tyrosine kinase inhibitors (TKI) within 7 days prior to leukapheresis,
    • Fludarabine/clofarabine or immunosuppressive drugs and antibodies (e.g. rituximab, calcineurin inhibitors, blinatumomab) or investigational drugs or donor lymphocyte transfusions or radiation therapy within 30 days prior to apheresis,
    • Alemtuzumab within 3 months prior to leukapheresis,
    • Exception: Intrathecal chemotherapy is allowed prior to treatment, but should be discontinued in ALL and BL 10 days prior to MB-CART19.1 infusion to limit risk of neurotoxicities;
  • Hypersensitivity against any drug or its ingredients/impurities that is scheduled or likely to be given during trial participation, e.g. as part of the mandatory lymphodepletion protocol, pre-medication for infusion, rescue medication/salvage therapies for treatment related toxicities;
  • Intake of concomitant medication contraindicated for other reasons than hypersensitivity, e.g. live vaccines and fludarabine;
  • Contraindication of trial related procedures as judged by the investigator, e.g. lumbar punctures for CSF sampling;
  • Female patients of child-bearing potential not willing to practice a highly effective form of birth control from the time of enrollment and for 12 months after dosing the IMP;
  • Male patients of fathering potential not willing to practice a highly effective form of birth control from the time of enrollment and for 12 months after dosing the IMP;
  • Concurrent participation in another interventional trial that could interact with this trial, e.g. CAR T trials;
  • Cerebral dysfunction, legal incapacity of adult patients;
  • Committal to an institution on judicial or official order.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03853616


Contacts
Layout table for location contacts
Contact: Alisa Yakushina +4916098973562 Alisa.yakushina@miltenyi.com
Contact: Christine Schubert +49 2204 8306 6564 christine.schubert@miltenyi.com

Locations
Layout table for location information
Germany
Charité - University clinic, pediatric clinic with focus on oncology and hematology Recruiting
Berlin, Germany, 13353
Contact: Annette Kuenkele, Dr.    +49 30 450 616 178    annette.kuenkele@charite.de   
Contact: Arend von Stackelberg, PD, Dr.    +49 30 450 666 833    arend.stackelberg@charite.de   
University clinic, clinical for children and youth Active, not recruiting
Erlangen, Germany, 91054
Universitätsklinikum Erlangen Recruiting
Erlangen, Germany, 91054
Contact: Andreas Mackensen, Prof.Dr.    0049 (0)9131 8535 954    andreas.mackensen@uk-erlangen.de   
Contact: Barbara Ferstl, Dr.    0049 (0)9131 8543 104    barbara.ferstl@uk-erlangen.de   
University medicine Goettingen, Clinic of hematology and medical oncology Recruiting
Göttingen, Germany, 37075
Contact: Justin Hasenkamp, Dr.    +49 55 139 651 82    justin.hasenkamp@med.uni-goettingen.de   
Contact: Gerald Wulf, Prof., Dr.    +49 55 139 170 577    gerald.wulf@med.uni-goettingen.de   
Children's Hospital of Dr. von Hauner by Ludwig-Maximilian University Recruiting
Munich, Germany, 80337
Contact: Tobias Feuchtinger, Prof., Dr.    +49 89 440 052 759    tobias.feuchtinger@med.uni-muenchen.de   
Contact: Vera Binder, Dr.    +49 89 440 052 875    vera.binder@med.uni-muenchen.de   
Universitätsklinikum Münster - Klink für Kinderheilkunde und Jugendmedizin / Pädiatrische Hämatologie und Onkologie Recruiting
Münster, Germany, 48149
Contact: Claudia Rössig, Prof. Dr.    0049 (0)251 83 47 741    rossig@ukmuenster.de   
Contact: Birgit Burkhardt, PD Dr.    0049 (0)251 83 52 840    birgit.burkhardt@ukmuenster.de   
Universitätsklinikum Münster - Medizinische Klinik A / KMT Zentrum Recruiting
Münster, Germany, 48149
Contact: Matthias Stelljes, Prof. Dr.    +49 251 83 52801    matthias.stelljes@ukmuenster.de   
Contact: Jan Henrik Mikesch, Dr.    +49 251 83 52801    jan-henrik.mikesch@ukmuenster.de   
Tuebingen University clinic, medical university clinic for internal medicine Recruiting
Tuebingen, Germany, 72076
Contact: Wolfgang Bethge, Prof., Dr.    +49 70 712 083 176    wolfgang.bethge@med.uni-tuebingen.de   
Contact: Christoph Faul, Dr.    +49 70 712 984 087    christoph.faul@med.uni-tuebingen.de   
University clinic for children and youth medicine Active, not recruiting
Tuebingen, Germany, 72076
University clinic, pediatric hematology and oncology Recruiting
Würzburg, Germany, 97070
Contact: Paul-Gerhardt Schlegel, Prof., Dr.    +49 93 120 127 999    schlegel_p@ukw.de   
Contact: Eyrich Matthias, Prof., Dr.    +49 93 120 127 620    eyrich_m@ukw.de   
Sponsors and Collaborators
Miltenyi Biomedicine GmbH
Investigators
Layout table for investigator information
Principal Investigator: Claudia Rössig, Prof. Dr. Univeristy Hospital Muenster
Layout table for additonal information
Responsible Party: Miltenyi Biomedicine GmbH
ClinicalTrials.gov Identifier: NCT03853616    
Other Study ID Numbers: M-2017-322
2017-002848-32 ( EudraCT Number )
First Posted: February 25, 2019    Key Record Dates
Last Update Posted: December 1, 2021
Last Verified: November 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Lymphoma, B-Cell
Leukemia, Lymphocytic, Chronic, B-Cell
Recurrence
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Disease Attributes
Pathologic Processes
Lymphoma, Non-Hodgkin
Leukemia, B-Cell